<DOC>
	<DOCNO>NCT00708773</DOCNO>
	<brief_summary>Describe dose-limiting toxicity ( DLT ) maximum tolerate dose ( MTD ) irinotecan cancer patient advance solid tumor UGT1A1 6/6 6/7 genotype .</brief_summary>
	<brief_title>Genotype-Directed Dose-Escalation Study Irinotecan Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm solid tumor lymphoma appropriate treatment irinotecan . 18 year old ECOG performance status 01 Life expectancy great 12 week . Normal organ marrow function define : leukocyte ≥ 3,000/μl absolute neutrophil count ≥ 1,500/μl platelet ≥ 100,000/μl total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 X institutional ULN ( ≤5 X ULN patient hepatic metastasis ) creatinine within normal institutional limit OR glomerular filtration rate ≥50 ml/min/1.73 m2 patient creatinine level institutional normal calculate modified MDRD equation recommend National Kidney Disease Education Program Measurable assessable disease . Able understand willing sign write informed consent document . Women childbearing potential men partner must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation . Patients UGT1A1 genotype 6/6 , 6/7 , 7/7 . Patients either one two rare allele ( i.e. , 5 allele 8 allele ) , carrier *6 allele enrol study . Patients blood drawn genotyping upon sign informed consent form study . Patients take statin therapy interrupt dose statin 3 day administration irinotecan cycle Biologic therapy , chemotherapy , radiotherapy , investigational agent within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study . Can receive investigational agent . Use colony growth factor within 3 week prior study entry . Posttransplant patient , may subject severe neutropenia . Uncontrolled brain metastasis . Patients brain metastasis must stable neurologic status steroid anticonvulsant least 4 week must without neurologic dysfunction would confound evaluation neurologic adverse event . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude study irinotecan agent potential teratogenic abortifacient effect . Breastfeeding stop . HIVpositive patient , patient immune deficiency increase risk lethal infection treat marrowsuppressive therapy . History inflammatory bowel disease require therapy patient chronic diarrhea syndrome paralytic ileus . Patients undergone major surgical procedure , open biopsy significant traumatic injury within 28 day prior start therapy participate . Patients prior pelvic irradiation participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>